Compare Stocks

Date Range: 

 NovoheartOxford BioDynamicsReNeuron GroupUniverse Pharmaceuticalse-therapeutics
SymbolCVE:NVHLON:OBDLON:RENENYSE:UPCLON:ETX
Price Information
Current PriceC$0.53GBX 75GBX 134$3.33GBX 27.90
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.50.60.00.4
Analysis Score0.00.00.00.00.0
Community Score2.62.43.00.02.1
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market CapC$79.23 million£69.42 million£83.58 million$66.56 million£122.02 million
BetaN/AN/AN/AN/AN/A
Average Volume33,593149,585243,7514,184,108917,003
Sales & Book Value
Annual RevenueC$423,500.00£456,000.00£112,000.00N/A£305,000.00
Price / Sales236.08152.24680.24N/A384.84
CashflowC$0.07 per shareGBX 11.91 per shareGBX 28.18 per shareN/AGBX 3.64 per share
Price / Cash7.466.304.75N/A7.66
Book ValueC$0.12 per shareGBX 14.70 per shareGBX 20.80 per shareN/AGBX 3.70 per share
Price / Book4.340.050.06N/A0.08
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.04)GBX (4.70)GBX (45.90)N/AGBX (1)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio27.62%3.98%11.98%N/A0.30%
Current Ratio6.13%10.01%1.77%N/A36.70%
Quick Ratio6.05%9.59%1.77%N/A35.91%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A3762N/A16
Shares Outstanding188.64 million92.56 million56.86 million21.75 million420.77 million
Next Earnings DateN/A6/14/2021 (Estimated)7/19/2021 (Estimated)N/A5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
e-Therapeutics plc - ETX to receive two payments from Galapagose-Therapeutics plc - ETX to receive two payments from Galapagos
proactiveinvestors.co.uk - April 23 at 1:04 PM
e-therapeutics reaches two key milestones in Galapagos collaboratione-therapeutics reaches two key milestones in Galapagos collaboration
proactiveinvestors.co.uk - April 23 at 8:04 AM
e-therapeutics sees two key milestones in Galapagos collaboratione-therapeutics sees two key milestones in Galapagos collaboration
proactiveinvestors.co.uk - April 23 at 8:04 AM
e-Therapeutics gets two payments from Galapagos under collaboratione-Therapeutics gets two payments from Galapagos under collaboration
lse.co.uk - April 23 at 8:04 AM
e-Therapeutics plc - Appointment of Chief Financial Officere-Therapeutics plc - Appointment of Chief Financial Officer
proactiveinvestors.co.uk - March 30 at 10:43 AM
E-therapeutics appoints Karl Keegan as CFOE-therapeutics appoints Karl Keegan as CFO
shareprices.com - March 29 at 9:58 AM
e-therapeutics appoints pharma veteran as CFOe-therapeutics appoints pharma veteran as CFO
proactiveinvestors.co.uk - March 29 at 9:58 AM
This penny stock is up 500% since January 2020. Should I buy now?This penny stock is up 500% since January 2020. Should I buy now?
fool.co.uk - March 16 at 3:11 PM
How Much Of e-therapeutics plc (LON:ETX) Do Insiders Own?How Much Of e-therapeutics plc (LON:ETX) Do Insiders Own?
finance.yahoo.com - March 3 at 7:24 AM
e-Therapeutics splits chief executive and executive chairman rolese-Therapeutics splits chief executive and executive chairman roles
proactiveinvestors.co.uk - March 1 at 8:51 AM
e-Therapeutics plc - Board Changese-Therapeutics plc - Board Changes
proactiveinvestors.co.uk - March 1 at 8:51 AM
e-Therapeutics plc - e-therapeutics to present at Shares Eveninge-Therapeutics plc - e-therapeutics to present at Shares Evening
proactiveinvestors.co.uk - February 16 at 9:57 AM
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
finance.yahoo.com - January 2 at 7:23 AM
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Planse-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
uk.finance.yahoo.com - October 19 at 8:36 AM
e-therapeutics Chairman Mortazavi takes over CEO duties, solving a big unmet need in the industrye-therapeutics Chairman Mortazavi takes over CEO duties, 'solving a big unmet need in the industry'
proactiveinvestors.com - October 12 at 3:46 PM
e-therapeutics re-energised as executive chairman Mortazavi takes over CEO dutiese-therapeutics re-energised as executive chairman Mortazavi takes over CEO duties
proactiveinvestors.co.uk - October 12 at 4:11 AM
e-Therapeutics plc - Appointment of Ali Mortazavi as CEOe-Therapeutics plc - Appointment of Ali Mortazavi as CEO
proactiveinvestors.co.uk - October 12 at 4:11 AM
Week Ahead: 12 -16 OctoberWeek Ahead: 12 -16 October
investorschronicle.co.uk - October 10 at 8:15 AM
Expansion of Scientific Advisory BoardExpansion of Scientific Advisory Board
sharecast.com - September 28 at 9:49 AM
e-Therapeutics expands scientific advisory boarde-Therapeutics expands scientific advisory board
proactiveinvestors.co.uk - September 28 at 9:49 AM
e-Therapeutics new boss sees lots of potentiale-Therapeutics' new boss sees lots of potential
proactiveinvestors.co.uk - August 7 at 2:14 PM
Ahmad Mortazavi Is The Executive Chairman of e-therapeutics plc (LON:ETX) And They Just Picked Up 3.4% More SharesAhmad Mortazavi Is The Executive Chairman of e-therapeutics plc (LON:ETX) And They Just Picked Up 3.4% More Shares
finance.yahoo.com - July 18 at 8:49 AM
e-Therapeutics unveils fundraising plans to enable next stage of growthe-Therapeutics unveils fundraising plans to enable next stage of growth
www.proactiveinvestors.co.uk - July 8 at 10:10 AM
BRIEF-E-Therapeutics Announces Conditional Offer For Subscription Via PrimarybidBRIEF-E-Therapeutics Announces Conditional Offer For Subscription Via Primarybid
uk.reuters.com - July 7 at 1:20 PM
BRIEF-E-Therapeutics Announces Collaboration With GalapagosBRIEF-E-Therapeutics Announces Collaboration With Galapagos
uk.reuters.com - June 11 at 1:07 AM
DateCompanyBrokerageAction
6/16/2020Oxford BioDynamicsShore CapitalReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.